↓ Skip to main content

Cancer Mortality Among Recipients of Solid-Organ Transplantation in Ontario, Canada

Overview of attention for article published in JAMA Oncology, April 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

30 news outlets
3 blogs
25 X users
3 Facebook pages
1 Google+ user


174 Dimensions

Readers on

106 Mendeley
Cancer Mortality Among Recipients of Solid-Organ Transplantation in Ontario, Canada
Published in
JAMA Oncology, April 2016
DOI 10.1001/jamaoncol.2015.5137
Pubmed ID

Sergio A. Acuna, Kimberly A. Fernandes, Corinne Daly, Lisa K. Hicks, Rinku Sutradhar, S. Joseph Kim, Nancy N. Baxter


Solid-organ transplant recipients (SOTRs) are at greater risk of developing some cancers than the general population; however, because they are also at increased risk of mortality from noncancer causes, the effect of transplantation on cancer mortality is unclear. To describe cancer mortality in SOTRs and to assess whether SOTRs are at increased risk of cancer mortality compared with the general population. Population-based cohort study of patients who underwent solid-organ transplantation in Ontario, Canada, between 1991 and 2010 with 85 557 person-years of follow-up through December 31, 2011. Solid-organ transplantation was identified using the national transplant register and linked to the provincial cancer registry and administrative databases. The analysis was conducted between November 2013 and February 2015. Solid-organ transplantation. Cancer mortality for SOTRs was compared with that of the general population using standardized mortality ratios (SMRs). Mortality and cause of death were ascertained by record linkage between the Canadian Organ Replacement Register, the Ontario Cancer Registry, and the Office of the Registrar General of Ontario death database. A total of 11 061 SOTRs were identified, including 6516 kidney, 2606 liver, 929 heart, and 705 lung transplantations. Recipients had a median (interquartile range) age of 49 (37-58) years, and 4004 (36.2%) were women. Of 3068 deaths, 603 (20%) were cancer related. Cancer mortality in SOTRs was significantly elevated compared with the Ontario population (SMR, 2.84 [95% CI, 2.61-3.07]). The risk remained elevated when patients with pretransplant malignant neoplasms (n = 1124) were excluded (SMR, 1.93 [95% CI, 1.75-2.13]). The increased risk was observed irrespective of transplanted organ. The SMR for cancer death after solid-organ transplantation was higher in children (SMR, 84.61 [95% CI, 52.00-128.40]) and lower in patients older than 60 years (SMR, 1.88 [95% CI, 1.62-2.18]) but remained elevated compared with the general population at all ages. Cancer death rate in SOTRs was increased compared with that expected in the general population; cancer was the second leading cause of death in these patients. Advances in prevention, clinical surveillance, and cancer treatment modalities for SOTRs are needed to reduce the burden of cancer mortality in this population.

X Demographics

X Demographics

The data shown below were collected from the profiles of 25 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 106 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Germany 1 <1%
Canada 1 <1%
Unknown 104 98%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 13 12%
Student > Master 13 12%
Researcher 12 11%
Other 11 10%
Student > Postgraduate 10 9%
Other 23 22%
Unknown 24 23%
Readers by discipline Count As %
Medicine and Dentistry 52 49%
Nursing and Health Professions 5 5%
Immunology and Microbiology 3 3%
Biochemistry, Genetics and Molecular Biology 2 2%
Pharmacology, Toxicology and Pharmaceutical Science 2 2%
Other 10 9%
Unknown 32 30%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 262. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 November 2018.
All research outputs
of 26,017,215 outputs
Outputs from JAMA Oncology
of 3,346 outputs
Outputs of similar age
of 318,395 outputs
Outputs of similar age from JAMA Oncology
of 106 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,346 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 84.3. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 318,395 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 106 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.